Abstract
Objective. To elaborate the model of the therapeutic treatment on the basis of its medico-economic analysis.
Methods. ABC-, frequency, VEN-analyses have been used as well as the Delphi method, integrated matrixes of ABC-VEN- and ABC-XYZ-analyses,
aggregate analysis and sensitivity analysis.
Results. First the summary table has been formed of the medicaments used in treatment of patients in 2011. While verifying codes of the anatomictherapeutic-
chemical classification the total portion of medicaments has made up 31.1 % of the profile medicaments. The results of the ABC-analysis
have reported that 10 medicaments of group A (5.1 % of the total number of items) have got 77.7 % of the total expenditure. Simdax (26.2 %),
pentaglobin 5 % (20.1 %), meronem (11.8 %) have made up the largest portion in the medicament budget. XYZ-analysis has reported that in average
84.6 % of items of the list of medicaments used for the therapeutic treatment have been consumed irregular and have been lack of stable demand
(category Z). More over 4.2 % of medicaments have had the mean stability of consumption (category Y). 11.2 % of medicaments for treatment of
the blood circulation system diseases in infants have had the stable demand (category X). The results of formal VEN-analysis have reported that 151
medicaments of group V (76.4 % of the total amount) have got 84.7 % of the total expenditure; 46 medicaments of group N (23.4 % of the total
amount) (other medicaments not included into the standard) made up 15.3 % of the total expenditure. The moderate extent of the specialists' agreement
has been observed when appraising the efficacy of medicinal therapy by clinical subdivisions (the Kendall rank coefficient 0.29, p < 0.001).
The results of the expert VEN-analysis have reported that 60.1 % of funds have been spent on 33 medicaments of group V (16.8 % of the total number),
35.6 % on 69 medicaments of group E (35.0 %), 4.4 % on 95 medicaments of group N (48.2 %). One-factor sensitivity analysis has reported
that the impact of the maximum permissible retail price including VAT has had the greatest proportion of all variables.
Conclusion. In order to appraise the rationality of using resources on the medicaments the multifactor-cascade-medico-economic analysis has
remained the method of option. According to the results of the conducted research in general it should be noted that the medicinal therapy has been
applied rationally. But there exist possibilities to save the funds of the organization by making more efficient communication between specialists of
clinical profile and marketing department.
References
1. Бокерия Л.А., Ступаков И.Н., Самородская И.В., Гришина С.Н., Беспалова Е.Д. Проблемы организации
кардиохирургической помощи детям с ВПС в РФ в условиях дефицита ресурсов. Главврач. 2003; 8: 29–32.
2. Вялков А.И., Кучеренко В.И. Клинический менеджмент. М.: Медицина; 2006.
3. Шпигель А.С. Клинико-экономический анализ и разработка формулярной системы на основе доказательной медицины:
расширение возможностей для антигомотоксической фармакотерапии. Биологическая медицина. 2004; 1: 15–20.
4. Fattinger K., Roos M., Vergeres P. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal
medicine. Br. J. Clin. Pharmacol. 2000; 49 (2): 158–67.
5. Авксентьева М.В., Герасимов В.Б., Воробьев П.А. Методологические проблемы проведения и практического внедрения
результатов клинико-экономического анализа. Проблемы стандартизации в здравоохранении. 2001; 4: 3–8.
About the authors
Stupakov Igor' Nikolaevich, Doctor of Medical Sciences, professor, director assistant on scientific-organizational work and management;
Zolotarev Nikita Yur'evich, post-graduate, economist
